Next Article in Journal
Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus
Next Article in Special Issue
A Microfluidic System for the Investigation of Tumor Cell Extravasation
Previous Article in Journal
Cardiac Arrhythmia Classification by Multi-Layer Perceptron and Convolution Neural Networks
Previous Article in Special Issue
Efficient Computational Design of a Scaffold for Cartilage Cell Regeneration
 
 
Article

A Cardiac Cell Outgrowth Assay for Evaluating Drug Compounds Using a Cardiac Spheroid-on-a-Chip Device

1
Division of Biotechnology, Department of Physics, Chemistry and Biology (IFM), Linköping University, 58183 Linköping, Sweden
2
Boehringer Ingelheim Pharma GmbH and Co. KG, Nonclinical Drug Safety Germany, D-88397 Biberach an der Riss, Germany
3
Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany
*
Authors to whom correspondence should be addressed.
Bioengineering 2018, 5(2), 36; https://doi.org/10.3390/bioengineering5020036
Received: 9 March 2018 / Revised: 23 April 2018 / Accepted: 1 May 2018 / Published: 4 May 2018
(This article belongs to the Special Issue Advances in Micro-Bioreactor Design for Organ Cell Studies)
Three-dimensional (3D) models with cells arranged in clusters or spheroids have emerged as valuable tools to improve physiological relevance in drug screening. One of the challenges with cells cultured in 3D, especially for high-throughput applications, is to quickly and non-invasively assess the cellular state in vitro. In this article, we show that the number of cells growing out from human induced pluripotent stem cell (hiPSC)-derived cardiac spheroids can be quantified to serve as an indicator of a drug’s effect on spheroids captured in a microfluidic device. Combining this spheroid-on-a-chip with confocal high content imaging reveals easily accessible, quantitative outgrowth data. We found that effects on outgrowing cell numbers correlate to the concentrations of relevant pharmacological compounds and could thus serve as a practical readout to monitor drug effects. Here, we demonstrate the potential of this semi-high-throughput “cardiac cell outgrowth assay” with six compounds at three concentrations applied to spheroids for 48 h. The image-based readout complements end-point assays or may be used as a non-invasive assay for quality control during long-term culture. View Full-Text
Keywords: 3D cell culture; microfluidics; organ-on-a-chip; cardiac spheroids; cardiomyocytes; induced pluripotent stem cells (iPSCs); drug screening 3D cell culture; microfluidics; organ-on-a-chip; cardiac spheroids; cardiomyocytes; induced pluripotent stem cells (iPSCs); drug screening
Show Figures

Figure 1

MDPI and ACS Style

Christoffersson, J.; Meier, F.; Kempf, H.; Schwanke, K.; Coffee, M.; Beilmann, M.; Zweigerdt, R.; Mandenius, C.-F. A Cardiac Cell Outgrowth Assay for Evaluating Drug Compounds Using a Cardiac Spheroid-on-a-Chip Device. Bioengineering 2018, 5, 36. https://doi.org/10.3390/bioengineering5020036

AMA Style

Christoffersson J, Meier F, Kempf H, Schwanke K, Coffee M, Beilmann M, Zweigerdt R, Mandenius C-F. A Cardiac Cell Outgrowth Assay for Evaluating Drug Compounds Using a Cardiac Spheroid-on-a-Chip Device. Bioengineering. 2018; 5(2):36. https://doi.org/10.3390/bioengineering5020036

Chicago/Turabian Style

Christoffersson, Jonas, Florian Meier, Henning Kempf, Kristin Schwanke, Michelle Coffee, Mario Beilmann, Robert Zweigerdt, and Carl-Fredrik Mandenius. 2018. "A Cardiac Cell Outgrowth Assay for Evaluating Drug Compounds Using a Cardiac Spheroid-on-a-Chip Device" Bioengineering 5, no. 2: 36. https://doi.org/10.3390/bioengineering5020036

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop